Current issues and clinical evidence in tumor-infiltrating lymphocytes in breast cancer

Sung Gwe Ahn, Joon Jeong, Soon Won Hong, Woo Hee Jung

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

With the advance in personalized therapeutic strategies in patients with breast cancer, there is an increasing need for biomarker-guided therapy. Although the immunogenicity of breast cancer has not been strongly considered in research or practice, tumor-infiltrating lymphocytes (TILs) are emerging as biomarkers mediating tumor response to treatments. Earlier studies have provided evidence that the level of TILs has prognostic value and the potential for predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-positive breast cancer. Moreover, the level of TILs has been associated with treatment outcome in patients undergoing neoadjuvant chemotherapy. To date, no standardized methodology for measuring TILs has been established. In this article, we review current issues and clinical evidence for the use of TILs in breast cancer.

Original languageEnglish
Pages (from-to)355-363
Number of pages9
JournalJournal of Pathology and Translational Medicine
Volume49
Issue number5
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Tumor-Infiltrating Lymphocytes
Breast Neoplasms
Tumor Biomarkers
Therapeutics
Biomarkers
Drug Therapy
Research

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Histology

Cite this

@article{47860430277b4bd496fec326ba32ac92,
title = "Current issues and clinical evidence in tumor-infiltrating lymphocytes in breast cancer",
abstract = "With the advance in personalized therapeutic strategies in patients with breast cancer, there is an increasing need for biomarker-guided therapy. Although the immunogenicity of breast cancer has not been strongly considered in research or practice, tumor-infiltrating lymphocytes (TILs) are emerging as biomarkers mediating tumor response to treatments. Earlier studies have provided evidence that the level of TILs has prognostic value and the potential for predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-positive breast cancer. Moreover, the level of TILs has been associated with treatment outcome in patients undergoing neoadjuvant chemotherapy. To date, no standardized methodology for measuring TILs has been established. In this article, we review current issues and clinical evidence for the use of TILs in breast cancer.",
author = "Ahn, {Sung Gwe} and Joon Jeong and Hong, {Soon Won} and Jung, {Woo Hee}",
year = "2015",
month = "1",
day = "1",
doi = "10.4132/jptm.2015.07.29",
language = "English",
volume = "49",
pages = "355--363",
journal = "Journal of Pathology and Translational Medicine",
issn = "2383-7837",
publisher = "Korean Society of Pathologists",
number = "5",

}

Current issues and clinical evidence in tumor-infiltrating lymphocytes in breast cancer. / Ahn, Sung Gwe; Jeong, Joon; Hong, Soon Won; Jung, Woo Hee.

In: Journal of Pathology and Translational Medicine, Vol. 49, No. 5, 01.01.2015, p. 355-363.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Current issues and clinical evidence in tumor-infiltrating lymphocytes in breast cancer

AU - Ahn, Sung Gwe

AU - Jeong, Joon

AU - Hong, Soon Won

AU - Jung, Woo Hee

PY - 2015/1/1

Y1 - 2015/1/1

N2 - With the advance in personalized therapeutic strategies in patients with breast cancer, there is an increasing need for biomarker-guided therapy. Although the immunogenicity of breast cancer has not been strongly considered in research or practice, tumor-infiltrating lymphocytes (TILs) are emerging as biomarkers mediating tumor response to treatments. Earlier studies have provided evidence that the level of TILs has prognostic value and the potential for predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-positive breast cancer. Moreover, the level of TILs has been associated with treatment outcome in patients undergoing neoadjuvant chemotherapy. To date, no standardized methodology for measuring TILs has been established. In this article, we review current issues and clinical evidence for the use of TILs in breast cancer.

AB - With the advance in personalized therapeutic strategies in patients with breast cancer, there is an increasing need for biomarker-guided therapy. Although the immunogenicity of breast cancer has not been strongly considered in research or practice, tumor-infiltrating lymphocytes (TILs) are emerging as biomarkers mediating tumor response to treatments. Earlier studies have provided evidence that the level of TILs has prognostic value and the potential for predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-positive breast cancer. Moreover, the level of TILs has been associated with treatment outcome in patients undergoing neoadjuvant chemotherapy. To date, no standardized methodology for measuring TILs has been established. In this article, we review current issues and clinical evidence for the use of TILs in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84945911861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945911861&partnerID=8YFLogxK

U2 - 10.4132/jptm.2015.07.29

DO - 10.4132/jptm.2015.07.29

M3 - Article

AN - SCOPUS:84945911861

VL - 49

SP - 355

EP - 363

JO - Journal of Pathology and Translational Medicine

JF - Journal of Pathology and Translational Medicine

SN - 2383-7837

IS - 5

ER -